IL270876B2 - Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells - Google Patents

Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells

Info

Publication number
IL270876B2
IL270876B2 IL270876A IL27087619A IL270876B2 IL 270876 B2 IL270876 B2 IL 270876B2 IL 270876 A IL270876 A IL 270876A IL 27087619 A IL27087619 A IL 27087619A IL 270876 B2 IL270876 B2 IL 270876B2
Authority
IL
Israel
Prior art keywords
virus
cell
cells
oncolytic virus
domain
Prior art date
Application number
IL270876A
Other languages
English (en)
Hebrew (he)
Other versions
IL270876A (en
IL270876B1 (en
Original Assignee
Univ Central Florida Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Central Florida Res Found Inc filed Critical Univ Central Florida Res Found Inc
Publication of IL270876A publication Critical patent/IL270876A/en
Publication of IL270876B1 publication Critical patent/IL270876B1/en
Publication of IL270876B2 publication Critical patent/IL270876B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18732—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18745—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL270876A 2017-05-25 2018-05-25 Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells IL270876B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511010P 2017-05-25 2017-05-25
PCT/US2018/034655 WO2018218151A1 (en) 2017-05-25 2018-05-25 Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells

Publications (3)

Publication Number Publication Date
IL270876A IL270876A (en) 2020-01-30
IL270876B1 IL270876B1 (en) 2024-02-01
IL270876B2 true IL270876B2 (en) 2024-06-01

Family

ID=64397136

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270876A IL270876B2 (en) 2017-05-25 2018-05-25 Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells

Country Status (10)

Country Link
US (2) US11684637B2 (enExample)
EP (1) EP3630144A4 (enExample)
JP (2) JP7522426B2 (enExample)
KR (2) KR20240132124A (enExample)
CN (1) CN110891584B (enExample)
AU (1) AU2018273963B2 (enExample)
BR (1) BR112019024656A2 (enExample)
CA (1) CA3064897A1 (enExample)
IL (1) IL270876B2 (enExample)
WO (1) WO2018218151A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
SG11202107904PA (en) * 2019-01-24 2021-08-30 University Of Central Florida Research Foundation Inc Compositions and methods for stimulating natural killer cells
AU2020391178A1 (en) * 2019-11-25 2022-06-09 Ansun Biopharma, Inc. Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
CN111676245B (zh) * 2020-06-24 2022-09-13 武汉波睿达生物科技有限公司 一种含有HSV-1型溶瘤病毒的NFAT-Cre-CAR-T细胞及其应用
AU2021324767A1 (en) * 2020-08-12 2023-04-13 University Of Central Florida Research Foundation, Inc. Methods and compositions for stimulating gamma delta T cells
CN112852757A (zh) * 2021-02-01 2021-05-28 南京大学 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法
AU2022255538B2 (en) * 2021-04-08 2026-01-22 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
CN115678854A (zh) * 2021-07-29 2023-02-03 上海中医药大学 一种基因工程细胞及其制备方法和应用
CN116875547A (zh) * 2023-09-04 2023-10-13 山东德升细胞治疗工程技术有限公司 一种利用细胞外泌体激活nk细胞的体外扩增培养方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090214590A1 (en) * 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
US20110318355A1 (en) * 2008-11-21 2011-12-29 Centre National De La Recherche Scientifique Mutant proteins of the f protein of piv-5 and piv-2
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
US20140134162A1 (en) * 2006-12-08 2014-05-15 Macrogenics, Inc. Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibiting
WO2016046357A1 (en) * 2014-09-26 2016-03-31 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
WO2016069607A1 (en) * 2014-10-27 2016-05-06 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
US20170007685A1 (en) * 2013-11-05 2017-01-12 The Board Of Regents Of The University Of Texas System TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES
US20170056458A1 (en) * 2015-04-30 2017-03-02 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein or active fragment
US20170067080A1 (en) * 2012-01-24 2017-03-09 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
US20020187543A1 (en) * 2001-04-05 2002-12-12 Curiel David T. Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins
EP1945771A1 (en) 2005-10-28 2008-07-23 Novo Nordisk A/S Fusion proteins that bind effector lymphocytes and target cells
CA2670790A1 (en) * 2006-11-28 2008-06-05 Ghc Research Development Corporation Polypeptides comprising fas activation and nkg2d-ligand domains
WO2008140621A2 (en) * 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
BRPI0924123B8 (pt) 2008-12-22 2021-05-25 Oncos Therapeutics Oy vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro
EP2485758A1 (en) * 2009-10-09 2012-08-15 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
DK3578201T3 (da) * 2012-06-28 2023-05-08 Univ Of Central Florida Research Foundation Incorporated Fremgangsmåder og sammensætninger til naturlige dræberceller
WO2014041119A1 (en) * 2012-09-14 2014-03-20 Deutsches Krebsforschungszentrum Oncolytic viruses expressing immuno-nucleases
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
HK1246180A1 (zh) 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090214590A1 (en) * 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
US20140134162A1 (en) * 2006-12-08 2014-05-15 Macrogenics, Inc. Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibiting
US20110318355A1 (en) * 2008-11-21 2011-12-29 Centre National De La Recherche Scientifique Mutant proteins of the f protein of piv-5 and piv-2
US20170067080A1 (en) * 2012-01-24 2017-03-09 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
US20170007685A1 (en) * 2013-11-05 2017-01-12 The Board Of Regents Of The University Of Texas System TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES
WO2016046357A1 (en) * 2014-09-26 2016-03-31 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
WO2016069607A1 (en) * 2014-10-27 2016-05-06 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
US20170056458A1 (en) * 2015-04-30 2017-03-02 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein or active fragment

Also Published As

Publication number Publication date
CN110891584B (zh) 2024-02-13
WO2018218151A1 (en) 2018-11-29
KR20240132124A (ko) 2024-09-02
AU2018273963B2 (en) 2023-07-20
JP2020521447A (ja) 2020-07-27
US11684637B2 (en) 2023-06-27
US12312393B2 (en) 2025-05-27
CN110891584A (zh) 2020-03-17
JP2024133640A (ja) 2024-10-02
CA3064897A1 (en) 2018-11-29
IL270876A (en) 2020-01-30
US20210145876A1 (en) 2021-05-20
EP3630144A4 (en) 2021-03-31
KR102700175B1 (ko) 2024-08-30
US20240000842A1 (en) 2024-01-04
BR112019024656A2 (pt) 2020-06-09
EP3630144A1 (en) 2020-04-08
JP7522426B2 (ja) 2024-07-25
IL270876B1 (en) 2024-02-01
KR20200010405A (ko) 2020-01-30
AU2018273963A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
US12312393B2 (en) Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
US11299549B2 (en) Humanized BCMA antibody and BCMA-CAR-T cells
CN105611943B (zh) 能结合CD32B和CD79b的双特异性单价Fc双抗体及其用途
US20210253667A1 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
CN110300603B (zh) Cd47-car-t细胞
JP7683932B2 (ja) ナチュラルキラー細胞を刺激するための組成物及び方法
WO2018118494A2 (en) Use of car-modified human natural killer cells to treat cancer
CN107922951A (zh) 抗磷脂酰肌醇蛋白聚糖‑1‑免疫抗原受体
CN111454909A (zh) 天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
US20250388695A1 (en) Epcam-cd3 epsilon bispecific antibodies
US12528873B2 (en) Humanized BCMA antibody and BCMA-CAR-T cells
US20170348403A1 (en) Adherent cancer cell line expressing a hematological tumor antigen
JP2024523011A (ja) 抗体－ｎｋｇ２ｄリガンドドメイン融合タンパク質
RU2839664C2 (ru) Композиции и способы для стимуляции естественных клеток-киллеров
WO2025140480A1 (zh) 经改造的iNKT细胞
HK40064903A (en) Chimeric antigen receptors, compositions and methods
HK1224942A1 (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
HK1224942B (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof